Skip to main content
    G

    Grace Therapeutics, Inc. (GRCE)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.75
    -0.06 (-3.31%)

    Market Cap: $38.08M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Grace Therapeutics, Inc. (GRCE) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Grace Therapeutics (GRCE) to earn -$0.76 per share in the fiscal year ending Mar 31, 2027. Over the last 30 days, 0 estimates for the fiscal year ending Mar 31, 2027 were revised up and 1 down. For the fiscal year ending Mar 31, 2028, the EPS consensus is -$0.60.

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Mar 31, 2027
    -$0.76
    EPS consensus
    Fiscal year ending Mar 31, 2028
    -$0.60
    EPS consensus

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analysts
    Mar 31, 2027-$0.76-$0.76 to -$0.761
    Mar 31, 2028-$0.60-$0.60 to -$0.601

    Quarterly Estimates

    The EPS consensus rises from -$0.21 for the quarter ending Dec 31, 2026 to -$0.12 for the quarter ending Mar 31, 2027.

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.21-$0.21 to -$0.211
    Mar 31, 2027-$0.12N/A3

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 1 upward and 3 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Mar 31, 202701
    Fiscal year ending Mar 31, 202811
    Quarter ending Dec 31, 202601

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Mar 31, 2027 has worsened from -$0.74.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Mar 31, 2027-$0.76-$0.76-$0.76-$0.76-$0.74N/A
    Fiscal year ending Mar 31, 2028-$0.60-$0.64-$0.64-$0.64-$0.77N/A
    Quarter ending Dec 31, 2026-$0.21-$0.18-$0.18-$0.21-$0.21N/A

    Frequently Asked Questions About GRCE

    What is the GRCE stock forecast?

    Consensus analyst estimates put Grace Therapeutics's EPS at -$0.76 for the fiscal year ending Mar 31, 2027.

    What EPS do analysts expect from GRCE next year?

    For the fiscal year ending Mar 31, 2027, the consensus EPS estimate is -$0.76, with estimates from -$0.76 to -$0.76 from 1 analyst. For the fiscal year ending Mar 31, 2028, the consensus EPS estimate is -$0.60, with estimates from -$0.60 to -$0.60 from 1 analyst.

    How many analysts cover GRCE?

    1 analyst estimates EPS for Grace Therapeutics for the fiscal year ending Mar 31, 2027.